US 12,102,680 B2
Anti-TIGIT antibodies
Sybil M. G. Williams, Wayland, MA (US); Drake LaFace, Half Moon Bay, CA (US); Laurence Fayadat-Dilman, Sunnyvale, CA (US); Gopalan Raghunathan, San Diego, CA (US); Linda Liang, Mountain View, CA (US); and Wolfgang Seghezzi, Mountain View, CA (US)
Assigned to Merck Sharp & Dohme LLC, Rahway, NJ (US)
Filed by Merck Sharp & Dohme LLC, Rahway, NJ (US)
Filed on May 15, 2020, as Appl. No. 16/806,658.
Application 16/806,658 is a division of application No. 15/817,691, filed on Nov. 20, 2017, granted, now 10,618,958.
Application 15/817,691 is a continuation of application No. 15/121,624, abandoned, previously published as PCT/US2015/045447, filed on Aug. 17, 2015.
Claims priority of provisional application 62/126,733, filed on Mar. 2, 2015.
Claims priority of provisional application 62/038,912, filed on Aug. 19, 2014.
Prior Publication US 2020/0270346 A1, Aug. 27, 2020
Int. Cl. A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/39541 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 30 Claims
 
1. A method of treating a human subject with cancer in need thereof, comprising administering to the subject an effective amount of a monoclonal antibody or antigen binding fragment thereof that binds to human TIGIT, wherein the monoclonal antibody and antigen binding fragment thereof comprise a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:88, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:89, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:90, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:91, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:92, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:93,
optionally in association with a further therapeutic agent or therapeutic procedure.